Autoimmune diseases involve self-tissue destruction by T-cells and antibodies due to lack of self-tolerance. The incidence of autoimmune disease is increasing. Autoimmune diseases can affect almost any part of the body. Antibody therapy is used in numerous diseases including rheumatoid arthritis, multiple sclerosis, lupus, myasthenia gravis, immune thrombocytopenia and skin blistering diseases.
ARGX-113 is a first-in-class antibody fragment designed for the treatment of patients with severe autoimmune diseases associated with high levels of pathogenic immunoglobulin G, or IgG, antibodies for which few innovative biologic treatments have been approved and severe unmet medical need exists. ARGX-113 has been created to degrade circulating disease-causing autoimmune antibodies and has potential in many large and orphan indications: multiple sclerosis, immune thrombocytopenia, systemic lupus erythematosus, myasthenia gravis and skin blistering diseases.